Imaging tumors using a new dual-target agent

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of a novel dual-target imaging agent, 68Ga-RM26-RGD, for PET/CT imaging in patients with breast, brain, and prostate cancers. The approach aims to improve tumor visualization by targeting specific receptors that are highly expressed in malignant tissues and their associated neovascularization. By comparing this new agent with conventional imaging methods, the study seeks to enhance diagnostic accuracy for tumors that typically show low uptake in standard imaging. Patients will undergo PET/CT scans using both the new agent and traditional imaging agents to assess the clinical application value of this dual-target approach.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* patients with confirmed or suspected breast/brain/prostate cancer;
* 68Ga-RM26-RGD and 18F-FDG(or 68Ga-RM26 or 68Ga-RGD) PET/CT within 2 week;
* signed written consent.

Exclusion Criteria:

* pregnancy;
* breastfeeding;
* any medical condition that in the opinion of the investigator may significantly interfere with study compliance.

Where it's running

• Peking Union Medical College Hospital
  Beijing, China Recruiting

Study contacts

• Principal investigator: Zhaohui Zhu, MD,PHD — Peking Union Medical College Hospital
• Study coordinator: Zhaohui Zhu, MD,PHD
• Email: 13611093752@163.com
• Phone: 86+13611093752

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Using brodalumab to treat immune-related side effects from cancer therapy

  This study is testing if brodalumab can help cancer patients who are having immune-related side effects from their immunotherapy treatment feel better.

  Recruiting Phase 1 Columbia University · New York, New York · NCT06673329

• Evaluating the impact of MR-guided radiation therapy on cancer treatment outcomes

  This study is testing how using a special type of radiation therapy with real-time imaging can improve treatment results and quality of life for adults with cancer.

  Recruiting at 14 sites UMC Utrecht · Pittsburgh, Pennsylvania and 17 other locations · NCT04075305

• Targeted radiopharmaceuticals for GRPR-positive cancers in adults

  A phase 1 study tests two targeted radiopharmaceuticals, radiolabeled Lu-177 and Ac-225 compounds, to treat GRPR-expressing breast, prostate, colorectal, and other solid tumors in adults who have not benefited from standard therapies.

  Recruiting Phase 1 Alpha-9 Oncology USA Inc. · Melbourne N., Victoria and 1 other locations · NCT07661641

• HER2 FPBMC therapy for metastatic breast and prostate cancer

  This study tests whether infusing patients with their own immune cells, armed with a HER2-targeting antibody, can help treat metastatic breast or prostate cancer.

  Recruiting Phase 1/2 University of Virginia · Charlottesville, Virginia · NCT07441889

• Digital app to support oncologist‑initiated genetic testing

  This project tests a digital app (GA‑Mainstream) to help oncologists offer germline genetic testing to adults with breast, prostate, colon, or other GI cancers.

  Recruiting at 2 sites Unity Health Toronto · Toronto, Ontario and 1 other locations · NCT07387263

• OCT-598 for advanced solid tumors

  This trial tests whether OCT-598, by itself or with docetaxel, is safe and to find the best dose for adults with advanced solid tumors who have limited standard treatment options.

  Recruiting at 2 sites Phase 1 Oscotec Inc. · Goyang-si and 2 other locations · NCT07358806

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.